Julia Jones
Directeur Financier/CFO chez AMO Pharma Ltd.
Profil
Julia Jones is currently the Chief Financial Officer & Director at AMO Pharma Ltd.
and also holds the position of Director & Finance Director at Curve Therapeutics Ltd.
She completed her undergraduate degree from Loughborough University in 1997.
Postes actifs de Julia Jones
| Sociétés | Poste | Début |
|---|---|---|
AMO Pharma Ltd.
 AMO Pharma Ltd. BiotechnologyHealth Technology AMO Pharma Ltd. engages in the development of biopharmaceutical products. It develops and identifies and advance therapies for people affected by serious and debilitating diseases, particularly rare or orphan diseases. The company was founded by Michael F. Snape on February 10, 2015 and is headquartered in Leeds, United Kingdom. | Directeur Financier/CFO | 14/10/2021 |
Curve Therapeutics Ltd.
 Curve Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Curve Therapeutics Ltd. operates as a drug-discovery company. It engages on the development of innovative technologies to address undruggable disease-modifying targets, with an in-house focus on cancer. The company was founded in 2019 and is headquartered in London, the United Kingdom. | Directeur Financier/CFO | - |
Formation de Julia Jones
| Loughborough University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
AMO Pharma Ltd.
AMO Pharma Ltd. BiotechnologyHealth Technology AMO Pharma Ltd. engages in the development of biopharmaceutical products. It develops and identifies and advance therapies for people affected by serious and debilitating diseases, particularly rare or orphan diseases. The company was founded by Michael F. Snape on February 10, 2015 and is headquartered in Leeds, United Kingdom. | Health Technology |
Curve Therapeutics Ltd.
Curve Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Curve Therapeutics Ltd. operates as a drug-discovery company. It engages on the development of innovative technologies to address undruggable disease-modifying targets, with an in-house focus on cancer. The company was founded in 2019 and is headquartered in London, the United Kingdom. | Commercial Services |
